公开(公告)号：US12037541B2

公开(公告)日：2024-07-16

申请号：US17451086

申请日：2021-10-15

申请人： CHINA PETROLEUM & CHEMICAL CORPORATION ,  SHANGHAI RESEARCH INSTITUTE OF PETROCHEMICAL TECHNOLOGY, SINOPEC

发明人： Yingcheng Li ,  Songyuan Gu ,  Weidong Zhang ,  Xinning Bao ,  Ou Sha ,  Zhiqin Shen ,  Yiqing Yang ,  Xiaodong Zhai

IPC分类号： C09K8/584 ,  C07C213/06 ,  C07C217/08 ,  C07C231/14 ,  C07C233/05 ,  C07C233/09 ,  C07C233/36 ,  C07C237/08 ,  C07C237/40 ,  C07C303/22 ,  C07C309/10 ,  C09K8/60

CPC分类号： C09K8/584 ,  C07C213/06 ,  C07C217/08 ,  C07C231/14 ,  C07C233/05 ,  C07C233/09 ,  C07C233/36 ,  C07C237/08 ,  C07C237/40 ,  C07C303/22 ,  C07C309/10 ,  C09K8/602

摘要： An anionic-cationic-nonionic surfactant represented by the formula (I)




exhibits significantly improved interfacial activity and stability as compared with the prior art. With the present anionic-cationic-nonionic surfactant, a flooding fluid composition for tertiary oil recovery with improved oil displacement efficiency and oil washing capability as compared with the prior art could be produced.

公开(公告)号：US20230124576A1

公开(公告)日：2023-04-20

申请号：US17983563

申请日：2022-11-09

申请人： SHENZHEN CATALYS TECHNOLOGY CO., LTD

发明人： Qiwei LANG ,  Xiaobing DING ,  Yang XIAO

IPC分类号： C07F17/02 ,  B01J31/22 ,  C07C37/00 ,  C07C237/08 ,  C07C29/145 ,  C07C41/18 ,  C07D213/30 ,  C07D333/16

摘要： Disclosed are a chiral multidentate ligand (I), a preparation, and an application thereof. In this method, compound (M1) is subjected to condensation with compound (M2) followed by amine deprotection in the presence of a deprotection reagent to obtain compound (M4). Compound (1) is subjected to deprotonation by butyl lithium and phosphorization followed by dimethylamino group substitution to produce compound (3). The compound (3) and the compound (M4) are reacted in the presence of triethylamine to produce chiral multidentate ligands.

公开(公告)号：US11458158B2

公开(公告)日：2022-10-04

申请号：US16867291

申请日：2020-05-05

申请人： Massachusetts Institute of Technology

发明人： Yizhou Dong ,  Kevin Thomas Love ,  Robert S. Langer ,  Daniel Griffith Anderson ,  Delai Chen ,  Yi Chen ,  Arturo Jose Vegas ,  Akinleye C. Alabi ,  Yunlong Zhang

IPC分类号： A61K31/7105 ,  C07D233/64 ,  C07D403/06 ,  C07D241/08 ,  C07C229/12 ,  C07C229/22 ,  C07C229/26 ,  C07D487/06 ,  C07D207/16 ,  C07D209/20 ,  C07C271/22 ,  C07C229/36 ,  C07C237/08 ,  C07C237/12 ,  C12N15/88 ,  C12N15/87 ,  C07C229/24 ,  C07C279/14 ,  C07C323/58 ,  C07D209/24 ,  C07D265/32 ,  C07D413/06 ,  C07D487/04 ,  C12Q1/02 ,  G01N33/15 ,  A61K31/711 ,  A61K47/22

摘要： Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R′, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.

公开(公告)号：US20220242820A1

公开(公告)日：2022-08-04

申请号：US17658075

申请日：2022-04-05

申请人： Nitto Denko Corporation

发明人： Roger Adami ,  Hao Bai ,  John Gaudette ,  Bharat Majeti ,  Seiji Nukui ,  Kwok Yin Tsang ,  Hai Wang ,  Haiqing Yin ,  Wenbin Ying

IPC分类号： C07C271/16 ,  C07D205/04 ,  C07D207/12 ,  C07C237/16 ,  C07D207/09 ,  C07D211/86 ,  C07D211/82 ,  C07D211/74 ,  C07F9/06 ,  A61K31/713 ,  C07F9/10 ,  A61K31/7105 ,  A61K9/127 ,  A61K9/51 ,  C07C237/08 ,  C07C237/50 ,  A61K47/16 ,  A61K47/22 ,  A61K47/24

摘要： Ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, the compounds, compositions and methods are to provide nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.

公开(公告)号：US11384051B2

公开(公告)日：2022-07-12

申请号：US16228054

申请日：2018-12-20

申请人： Nitto Denko Corporation

发明人： Roger Adami ,  Hao Bai ,  John Gaudette ,  Bharat Majeti ,  Seiji Nukui ,  Kwok Yin Tsang ,  Hai Wang ,  Haiqing Yin ,  Wenbin Ying

IPC分类号： A61K31/713 ,  A61K31/7105 ,  A61K9/127 ,  A61K9/51 ,  A61K47/16 ,  A61K47/22 ,  A61K47/24 ,  C07C271/16 ,  C07D205/04 ,  C07D207/12 ,  C07C237/16 ,  C07D207/09 ,  C07D211/86 ,  C07D211/82 ,  C07D211/74 ,  C07F9/06 ,  C07F9/10 ,  C07C237/08 ,  C07C237/50

摘要： This invention includes ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.

公开(公告)号：US11084813B2

公开(公告)日：2021-08-10

申请号：US15634272

申请日：2017-06-27

申请人： Techfields Pharma Co., Ltd.

发明人： Chongxi Yu ,  Lina Xu

IPC分类号： C07D471/04 ,  C07C271/16 ,  C07C271/22 ,  C07D321/12 ,  C07C219/10 ,  C07C219/14 ,  C07C219/28 ,  C07C229/12 ,  C07C327/30 ,  C07C229/58 ,  C07D455/02 ,  C07C237/06 ,  C07C237/20 ,  C07D207/16 ,  C07K5/083 ,  C07D211/62 ,  C07K5/097 ,  A61K31/137 ,  C07C229/36 ,  A61K31/195 ,  A61K31/198 ,  A61K31/277 ,  C07C317/44 ,  A61K31/197 ,  A61K31/24 ,  A61K31/40 ,  C07C219/06 ,  C07C219/32 ,  C07C237/08 ,  C07C327/36 ,  C07C217/60

摘要： One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

公开(公告)号：US10961181B2

公开(公告)日：2021-03-30

申请号：US16700304

申请日：2019-12-02

申请人： Nitto Denko Corporation

发明人： Yoshiro Niitsu ,  Victor Knopov ,  Joseph E. Payne ,  Zheng Hou ,  John A. Gaudette ,  Violetta Akopian ,  Richard P. Witte ,  Mohammad Ahmadian ,  Loren A. Perelman ,  Yasunobu Tanaka ,  Priya Karmali ,  Sridhar C. Nagarajan

IPC分类号： A61K31/713 ,  C07C237/08 ,  A61K47/54 ,  A61K9/00 ,  A61K9/10 ,  A61K9/127 ,  A61K47/18 ,  C12N15/113 ,  C07C323/60 ,  C07C333/04

摘要： Here described is a composition comprising a compound of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleoyl group; R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol; X is selected from a group consisting of —CH2—, —S—, and —O— or absent; Y is selected from —(CH2)n, —S(CH2)n, —O(CH2)n—, thiophene, —SO2(CH2)n—, and ester; n=1-4; a=1-4; b=1-4; c=1-4; and Z− is a counterion.

公开(公告)号：US20190209592A1

公开(公告)日：2019-07-11

申请号：US16182845

申请日：2018-11-07

申请人： BIOGEN MA INC.

发明人： Jermaine Thomas ,  Xiaogao Liu ,  Edward Yin-Shiang Lin ,  Guo Zhu Zheng ,  Bin Ma ,  Richard D. Caldwell ,  Kevin M. Guckian ,  Gnanasambandam Kumaravel ,  Arthur G. Taveras

IPC分类号： A61K31/695 ,  A61K31/11 ,  C07F7/08 ,  A61K31/165 ,  A61K31/137 ,  A61K31/235 ,  A61K31/223 ,  C07D401/06 ,  C07D277/64 ,  C07D239/74 ,  C07D217/04 ,  C07D215/227 ,  C07C255/54 ,  C07C47/575 ,  C07C43/247 ,  A61K45/06 ,  A61K31/683 ,  A61K31/662 ,  A61K31/517 ,  A61K31/472 ,  A61K31/4709 ,  A61K31/47 ,  A61K31/445 ,  A61K31/428 ,  A61K31/41 ,  A61K31/404 ,  A61K31/40 ,  A61K31/397 ,  A61K31/337 ,  A61K31/277 ,  A61K31/216 ,  A61K31/197 ,  A61K31/18 ,  C07F9/38 ,  A61K31/085 ,  C07F9/40 ,  C07D417/06 ,  C07D403/06 ,  C07D305/08 ,  C07D257/04 ,  C07D217/24 ,  C07D215/20 ,  C07D211/62 ,  C07D211/60 ,  C07D209/08 ,  C07D207/16 ,  C07D205/04 ,  C07C311/51 ,  C07C309/14 ,  C07C237/52 ,  C07C237/08 ,  C07C229/48 ,  C07C229/46 ,  C07C229/22 ,  C07C229/14 ,  A61K31/401 ,  A61K31/185 ,  A61K31/198 ,  A61K31/222

CPC分类号： A61K31/695 ,  A61K31/085 ,  A61K31/11 ,  A61K31/137 ,  A61K31/165 ,  A61K31/18 ,  A61K31/185 ,  A61K31/197 ,  A61K31/198 ,  A61K31/216 ,  A61K31/222 ,  A61K31/223 ,  A61K31/235 ,  A61K31/277 ,  A61K31/337 ,  A61K31/397 ,  A61K31/40 ,  A61K31/401 ,  A61K31/404 ,  A61K31/41 ,  A61K31/428 ,  A61K31/445 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/517 ,  A61K31/662 ,  A61K31/683 ,  A61K45/06 ,  C07C43/247 ,  C07C47/575 ,  C07C229/14 ,  C07C229/22 ,  C07C229/46 ,  C07C229/48 ,  C07C237/08 ,  C07C237/52 ,  C07C255/54 ,  C07C309/14 ,  C07C311/51 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07D205/04 ,  C07D207/16 ,  C07D209/08 ,  C07D211/60 ,  C07D211/62 ,  C07D215/20 ,  C07D215/227 ,  C07D217/04 ,  C07D217/24 ,  C07D239/74 ,  C07D257/04 ,  C07D277/64 ,  C07D305/08 ,  C07D401/06 ,  C07D403/06 ,  C07D417/06 ,  C07F7/081 ,  C07F9/3808 ,  C07F9/3834 ,  C07F9/4006

摘要： Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

公开(公告)号：US10308593B2

公开(公告)日：2019-06-04

申请号：US12634796

申请日：2009-12-10

申请人： Graham Jackson

发明人： Graham Jackson

IPC分类号： C07C229/12 ,  C07C237/08 ,  C07C229/24 ,  C07C237/06 ,  C07C237/10 ,  C10L1/14 ,  C10L1/22 ,  C10L1/222 ,  C10L1/224 ,  C10L10/00 ,  C10L10/14 ,  C10L10/18 ,  C10L1/16 ,  C10L1/19 ,  C10L1/197 ,  C10L1/198 ,  C10L1/223 ,  C10L1/2383

摘要： A fuel oil composition comprising a major amount of a fuel oil and a minor amount of a compound being the product of the 1,4-addition reaction of (i) ammonia, a primary or secondary hydrocarbyl-substituted amine or a mixture thereof to (ii) a species containing one or more α,β-unsaturated carbonyl groups, wherein the compound includes at least one hydrocarbyl group containing at least 10 carbon atoms. The fuel oil composition has improved low temperature properties.

公开(公告)号：US10272081B2

公开(公告)日：2019-04-30

申请号：US15884044

申请日：2018-01-30

申请人： Aquinox Pharmaceuticals (Canada) Inc.

发明人： Lloyd F. Mackenzie ,  Thomas B. MacRury ,  Curtis Harwig ,  David Bogucki ,  Jeffery R. Raymond ,  Jeremy D. Pettigrew ,  Vladimir Khlebnikov ,  Rudong Shan

IPC分类号： A61K31/05 ,  A61K31/09 ,  A61K31/10 ,  A61K31/12 ,  C07C39/17 ,  C07C43/21 ,  C07C43/23 ,  C07C49/83 ,  C07C49/84 ,  C07C62/32 ,  C07C62/34 ,  A61K31/085 ,  A61K31/095 ,  A61K31/122 ,  A61K31/135 ,  A61K31/155 ,  A61K31/165 ,  A61K31/166 ,  A61K31/167 ,  A61K31/192 ,  A61K31/4965 ,  C07D405/12 ,  C07C49/835 ,  C07C43/215 ,  C07D241/24 ,  C07D213/81 ,  C07D249/08 ,  C07D295/112 ,  C07D213/75 ,  C07D295/215 ,  C07D211/66 ,  C07C311/18 ,  C07D213/82 ,  C07D213/89 ,  C07D233/64 ,  C07D401/12 ,  C07C233/76 ,  C07D213/38 ,  C07C255/47 ,  C07C275/26 ,  C07C275/64 ,  C07C279/16 ,  C07C311/07 ,  C07C311/17 ,  C07C317/22 ,  C07C217/84 ,  C07C323/20 ,  C07C225/20 ,  C07C233/26 ,  C07C233/28 ,  C07C233/31 ,  C07C233/32 ,  C07C233/60 ,  C07C235/82 ,  C07C237/08 ,  A61K31/277 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4465 ,  A61K31/495 ,  A61K31/496

摘要： Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.